Schering Corporation

Novartis Ag

Novartis Pharma Gmbh

Paul William Glue

David L Cutler

Peter C Hiestand

Melton B Affrime

Kevin Hall McAllister

Janice K Albrecht

Vicki L Coffin

Eckhard Weber

Clifford A Brass

Edward Piken

Carlos O Stalgis

Carolyn An Foster

This invention relates to compounds of formula I, wherein the R, R, R, R, R, Rand Rare as defined in the specification, and, in particular, their use as pharmaceuticals, for use in the treatment of urinary incontinence. 

Use of neurokinin antagonists in the treatment of urinary incontinence

Methods of treating patients having susceptible viral infections, especially chronic hepatitis C infection by administering to said patient a therapeutically effective amount of a combination therapy of interferon-alfa and ribavirin for a time sufficient to lower HCV-RNA in association with a therapeutically effective amount of an antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis are disclosed.

HCV combination therapy

There is disclosed a method for treating antiviral treatment naives patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using (1) a therapeutically effective inducing amount of ribavirin and a therapeutically effective induction dosing amount of pegylated interferon-alfa, e.g, pegylated interferon-alfa-2b for a first treatment time period sufficient to substantially lower detectable HCV-RNA, followed by (2) administering a therapeutically effective amount of ribavirin and an therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b for a second treatment time period sufficient to eradicate detectable HCV-RNA at least by end of the second treatment time period and to maintain no detectable HCV-RNA for at least 24 weeks after the end of the second treatment time period.

Ribavirin-pegylated interferon alfa induction HCV combination therapy

A method comprising administering a PEG -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.

Polyethylene glycol modified interferon therapy

A method of reducing cravings in a mammal to nicotine or tobacco is disclosed. The method comprises administering to the mammal an effective amount of a D,/D,antagonist or a D,/D,partial agonist alone or in combination with other specified CNS compounds.

Method of reducing nicotine and tobacco craving in mammals

A method comprising administering a PEG,-IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.

A method comprising administering a PEG.sub.12000 -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.

Growing community of inventors

Flemington, NJ, United States of America

Paul William Glue